Antibodies to FeRn and uses thereof

Patent metadata

Field	Value
Publication number	US-9260520-B2
Application number	US-201414168839-A
Country	US
Kind code	B2
Filing date	Jan 30, 2014
Priority date	Apr 25, 2008
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

First claim

What is claimed is:

1. A method of treating an autoimmune disorder in a subject in need thereof, the method comprising:
administering to the subject in need thereof an effective amount of an antibody that binds human FcRn thereby treating the autoimmune disorder, wherein the antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, and wherein: the HC comprises:
a HC CDR1 comprising an amino acid sequence EYAMG (SEQ ID NO: 144) or VYAMG (SEQ ID NO:156),
a HC CDR2 comprising an amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:145), or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and
a HC CDR3 comprising an amino acid sequence LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or LAIGDSY (SEQ ID NO: 176); and

the LC comprises:
a LC CDR1 comprising an amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141),
a LC CDR2 comprising an amino acid sequence GDSQRPS (SEQ ID NO:142), and
a LC CDR3 comprising an amino acid sequence CSYAGSGIYV (SEQ ID NO: 143).

2. The method of claim 1 , wherein the HC comprises a HC CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:144), a HC CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 145), and a HC CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 176).

3. The method of claim 1 , wherein the HC comprises a HC CDR1 comprising the amino acid sequence VYAMG (SEQ ID NO:156), a HC CDR2 comprising the amino acid sequence SIGSSGGPTKYADSVKG (SEQ ID NO: 157), and a HC CDR3 comprising the amino acid sequence LSIVDSY (SEQ ID NO: 164).

4. The method of claim 1 , wherein the HC comprises, a HC CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:144), a HC CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 comprising the amino acid sequence LSTGELY (SEQ ID NO: 146).

5. The method of claim 1 , wherein the HC comprises: (i) a HC CDR1 of EYAMG (SEQ ID NO:144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LSTGELY (SEQ ID NO:146); (ii) a HC CDR1 of VYAMG (SEQ ID NO:156), a HC CDR2 of SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 of LSIRELV (SEQ ID NO:158); (iii) a HC CDR1 of VYAMG (SEQ ID NO:156), a HC CDR2 of SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 of LSIVDSY (SEQ ID NO:164); (iv) a HC CDR1 of EYAMG (SEQ ID NO: 144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LSLGDSY (SEQ ID NO:170); or (v) a HC CDR1 of EYAMG (SEQ ID NO: 144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LAIGDSY (SEQ ID NO:176).

6. The method of claim 1 , wherein the autoimmune disorder is a disorder selected from the group consisting of: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Myasthenia Gravis (MG), Graves Disease, Idiopathic Thrombocytopenia Purpura (ITP), Guillain-Barre Syndrome, autoimmune myocarditis, Membrane Glomerulonephritis, diabetes mellitus, Type I diabetes, multiple sclerosis, Raynaud's syndrome, autoimmune thyroiditis, gastritis, Celiac Disease, Vitiligo, Hepatitis, primary biliary cirrhosis, inflammatory bowel disease, spondyloarthropathies, experimental autoimmune encephalomyelitis, immune neutropenia, sarcoidosis, polymyositis, polyarteritis, cutaneous vasculitis, pemphigus , pemphigoid, Goodpasture's syndrome, Kawasaki's disease, systemic sclerosis, anti-phospholipid syndrome, and Sjogren's syndrome.

Assignees

• Dyax Corp
• Biogen Hemophilia Inc

Inventors

• Tenhoor Christopher
• Muruganandam Arumugam
• Ladner Robert Charles
• Wood Clive
• Bitonti Alan J
• Mcgivney James
• Mcdonnell Kevin
• Liu Liming
• DUMONT Jennifer
• Sato Aaron K
• Viswanathan Malini

Classifications

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K16/283 Primary

  against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851) · CPC title

• G01N2333/70535

  Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F) · CPC title

• C07K2317/20

  characterized by taxonomic origin · CPC title